Discover the latest in health: evidence‑based wellness tips, medical breakthroughs, nutrition guidance, fitness insights, and expert advice for a healthier, happier life.
Nairobi, Kenya – In a significant step forward in the fight against HIV, Kenya has begun a nationwide rollout of Lenacapavir, a long-acting injectable medication for HIV prevention. The program, launched on Thursday, February 26, 2026, offers a new, more convenient option for individuals at risk of contracting the virus, moving beyond the need for daily oral medication. The first doses were administered at Riruta Health Centre in Kawangware, Nairobi, marking a pivotal moment in the country’s public health strategy.
Lenacapavir represents a major advancement in HIV prevention, requiring administration only twice a year. This contrasts sharply with traditional Pre-Exposure Prophylaxis (PrEP), which necessitates daily pill consumption, often posing adherence challenges. The rollout is part of Kenya’s ambitious goal to reduce new HIV infections to zero by 2030, a target that Health Cabinet Secretary Aden Duale believes this innovation will significantly contribute to.
Samson Mutua, a 27-year-old community health practitioner, became the first Kenyan to receive the injection. “I volunteered for the program and am feeling protected,” Mutua stated after receiving his dose, noting that the injection provides six months of preventative protection after a full initiation with oral PrEP. The availability of Lenacapavir free of charge at public health facilities underscores the government’s commitment to accessible preventative healthcare.
Affordability and Access
The cost of Lenacapavir has been a concern globally, with the drug priced at over $28,000 (approximately €23,700) per patient annually in the United States, according to UNAIDS, which previously urged Gilead Sciences to lower its price. However, through negotiations with the manufacturer, Kenya will offer the injection for just 7,800 Kenyan shillings (approximately €50) per person per year, making it significantly more affordable and accessible to those who need it. This affordability is crucial given that approximately 1.3 million people in Kenya live with HIV, with a disproportionate number being young adults aged 15-24.
The rollout will occur in three phases, initially targeting 15 high-burden counties including Mombasa, Kilifi, Machakos, Nairobi, Kisumu, and Homa Bay – regions with the highest rates of new infections and overall HIV prevalence. The Ministry of Health received its first shipment of 21,000 doses last week, a collaborative effort between Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria.
Community Impact and Discreet Protection
Health workers are optimistic about the impact of Lenacapavir on community health. Carol Njomo, a community health worker in Kawangware, emphasized the increased discretion the injection offers compared to frequent visits to health centers for traditional PrEP. This is particularly important for individuals who may face stigma or logistical challenges in accessing regular healthcare.
The new preventative measure has been met with relief from those at high risk. Peace Lawrence, a 23-year-old sex worker, expressed her gratitude, stating, “It’s a relief,” as she often forgets to grab daily PrEP pills. “Having sex with multiple partners always leaves me in fear,” she confided to AFP.
Challenges and Future Outlook
The implementation of this program comes at a time when African nations are facing reductions in global humanitarian aid, including from the United States, which has impacted HIV/AIDS programs across the continent. Despite these challenges, the Kenyan government remains committed to expanding access to this life-saving preventative measure.
The introduction of Lenacapavir in Kenya, following its deployment in South Africa, Eswatini, and Zambia since December, positions the country at the forefront of innovative HIV prevention in East Africa. As the rollout progresses, monitoring its effectiveness and addressing potential logistical hurdles will be crucial to maximizing its impact on public health. The Ministry of Health will continue to assess the program’s reach and adapt strategies to ensure equitable access for all Kenyans at risk.
Disclaimer: This article provides informational content about health and medicine and should not be considered a substitute for professional medical advice. Always consult with a qualified healthcare provider for diagnosis and treatment of any health condition.
What are your thoughts on this new approach to HIV prevention? Share your comments below and facilitate us spread awareness!